Compare Eli Lilly And Co (LLY) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Tapestry, Inc. — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Tapestry, Inc. trades at $116.02 (market cap $23.09B). The key difference: Eli Lilly And Co is far larger — about 45× Tapestry, Inc.'s market cap, and Tapestry, Inc. pays the higher dividend (1.6%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Tapestry, Inc. for 70 Days on average.
| LLY | TPR | |
|---|---|---|
Market Cap | $1.04T | $23.09B |
Volume | 3,064,878 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $164.78 |
52-Week Low | $799.57 | $98.81 |
Typical Hold Time | 93 Days | 70 Days |
Enterprise Value | $1.09T | $25.89B |
Dividend Yield | 0.59% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
TPR trades at $116.26, up 2.53% today, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a high ROE of 197.14% highlight operational strength, though net income margin fell sharply in 2025. The stock is supported by a $174.64 consensus price target and positive news on international growth, but faces risks from tariffs and Kate Spade execution challenges.
Outlook remains positive with 73% buy ratings and projected revenue growth to $8.0B in 2026. Key opportunities include margin expansion and Coach brand momentum, while risks involve volatile cash flows, high debt, and competitive pressures. The current price offers a 50% upside to the consensus target, but investors should monitor earnings delivery and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
